Andrew Obenshain
About Andrew Obenshain
Andrew Obenshain is the CEO of a biotech company, known for his dedication to advancing therapies for rare diseases and his extensive background in the biotech sector, including roles at Shire and Genzyme.
Andrew Obenshain Title and Role
Andrew Obenshain is the Chief Executive Officer. Prior to his current role, he served as President, Severe Genetic Diseases. He took on the position of CEO in 2021 after holding various leadership roles within the company since joining in 2016.
Andrew Obenshain Education and Expertise
Andrew Obenshain holds an MBA from Northwestern University's Kellogg School of Management. His academic background also includes a B.A. in genetics, cell, and developmental biology from Dartmouth College. This education has provided a strong foundation for his career dedicated to advancing therapies for rare diseases.
Andrew Obenshain Background in Biotechnology
Andrew Obenshain began his career in the biotechnology sector, first working with small biotech companies in consulting and venture capital investing roles. This early experience paved the way for his subsequent positions at Genzyme and Sanofi, where he was involved in business development, marketing, and global commercial operations over a span of eight years.
Andrew Obenshain Leadership in Rare Disease Therapies
Andrew Obenshain has dedicated his career to improving the lives of patients and their families through advancements in therapies for rare diseases. Before becoming CEO, he served as President, Severe Genetic Diseases. His previous role at Shire as general manager of France and Benelux involved overseeing a portfolio of seven rare disease products.
Andrew Obenshain Career at the Company
Andrew Obenshain joined the company in 2016 as head of Europe. Over the years, he has risen through the ranks, eventually becoming CEO in 2021. His tenure has been marked by a strong focus on developing and advancing therapies for rare genetic disorders.